# psoriasis - grok-4.6

- Benchmark system: raw
- Repeat: 1
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: xAI / grok-4.6
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 4061
- Completion tokens: 3319
- Reasoning tokens: 
- Total tokens: 7380
- API requests reported: 
- Elapsed seconds: 41.421
- Final benchmark system: raw; file rank 1/5; original repeat 1; model vendor: xAI

---
**Overall biological interpretation**  
The lesional psoriatic skin transcriptomic profile is dominated by two interlocking processes: (1) marked epidermal hyperproliferation and reprogramming of terminal differentiation, and (2) intense innate-immune activation with antimicrobial and chemotactic outputs. The very large effect sizes (log2FC > 4–11) and extreme statistical significance for hundreds of genes indicate that the disease state is not merely a modest shift but a near-complete rewiring of keratinocyte biology and skin-resident innate immunity. Downregulation is comparatively modest and scattered, suggesting that the primary driver is gain-of-function in epidermal and innate programs rather than loss of protective genes.

**Core biological programs**  
Only five programs are identified, selected for biological centrality in psoriasis, minimal overlap, and support by multiple independent genes.

1. **Epidermal hyperproliferation and terminal differentiation**  
   Direction: strongly upregulated.  
   Major supporting genes: SPRR2A, SPRR2B, SPRR2D, SPRR2E, SPRR2F, SPRR2G, SPRR3, KRT6A, LCE3A, LCE3D, SERPINB3, SERPINB4, SERPINB13.  
   Pathway: GO keratinocyte differentiation; Reactome keratinization; KEGG skin barrier formation.  
   Explanation: These genes encode cornified-envelope precursors and hyperkeratotic keratins whose coordinated upregulation produces the thickened, parakeratotic stratum corneum characteristic of psoriasis plaques.  
   Evidence strength: direct (dataset log2FC and FDR), pathway/GO, disease-association (multiple published psoriasis transcriptomes). Limitation: largely reflects hyperproliferation secondary to upstream signals rather than primary causal lesions.

2. **Innate immune activation and IL-36/IL-1 family signaling**  
   Direction: strongly upregulated.  
   Major supporting genes: IL36A, IL36G, IL36RN, S100A7, S100A7A, S100A8, S100A12, CXCR2.  
   Pathway: Reactome IL-36 signaling; GO cytokine-mediated signaling pathway.  
   Explanation: IL-36 cytokines drive keratinocyte chemokine production and neutrophil recruitment; S100 proteins amplify TLR and RAGE signaling inside keratinocytes and provide alarmin activity.  
   Evidence strength: direct dataset, pathway evidence, disease-association (IL36/S100 loci are psoriasis GWAS hits). Limitation: expression may be partly leukocyte-derived given dermal infiltration.

3. **Antimicrobial peptide and defensin production**  
   Direction: strongly upregulated.  
   Major supporting genes: DEFB4A, DEFB4B, DEFB103A, DEFB103B, PI3 (possibly PI3-related), TMPRSS11D.  
   Pathway: GO antimicrobial humoral immune response; KEGG beta-defensin production.  
   Explanation: Coordinated defensin upregulation equips the epidermis with broad-spectrum antimicrobial activity but also creates a feed-forward loop that recruits and activates neutrophils.  
   Evidence strength: direct dataset (multiple DEFB genes), pathway evidence, disease-association (defensin loci linked to psoriasis). Limitation: defensins are also produced by neutrophils, blurring keratinocyte vs. leukocyte origin.

4. **Skin-barrier disruption and protease–antiprotease imbalance**  
   Direction: upregulated (SERPINs) with some coordinated downregulation of metabolic enzymes.  
   Major supporting genes: SERPINB3, SERPINB4, SERPINB11, SERPINB13, AKR1B10, CYP2W1 (down).  
   Pathway: GO extracellular matrix organization; Reactome serpin family.  
   Explanation: SerpinB overexpression inhibits kallikreins and other proteases, while AKR1B10/CYP2W1 shifts alter retinol and lipid metabolism, weakening the epidermal permeability barrier.  
   Evidence strength: direct dataset, pathway evidence, disease-association. Limitation: directionality of metabolic genes is mixed.

5. **Chemokine-driven immune-cell recruitment**  
   Direction: upregulated.  
   Major supporting genes: CXCL13, CXCR2, GJB2, GJB6.  
   Pathway: GO chemokine-mediated signaling pathway.  
   Explanation: CXCL13 recruits CXCR3+ T cells and neutrophils; connexin genes maintain keratinocyte–immune cell junctions.  
   Evidence strength: direct dataset, pathway evidence, disease-association. Limitation: contribution partly from infiltrating leukocytes.

**Key genes and interaction modules** (top 10)  
- SPRR2A (log2FC 7.31): central to cornified-envelope module; co-expression with other SPRR genes, pathway co-membership.  
- S100A7 / S100A8 (log2FC 7.09 / 7.73): alarmin–chemokine axis; co-expression, pathway co-membership.  
- IL36A (log2FC 11.37): master upstream driver of IL-36 signaling; regulatory interaction with IL36RN and IL36G.  
- DEFB4A / DEFB4B (log2FC 11.18 / 11.03): antimicrobial effector module; co-expression.  
- KRT6A (log2FC 4.30): keratinocyte activation marker; co-expression with SPRR and LCE genes.  
- SERPINB3 / SERPINB4 (log2FC 6.74 / 9.12): protease-inhibitor module; co-expression.  
- CXCL13 (log2FC 5.89): T-cell chemotactic signal; regulatory interaction with CXCR2.  
- LCE3A (log2FC 8.30): late-cornified-envelope component; pathway co-membership with SPRRs.  
- BTC (log2FC −4.30): downregulated EGFR ligand; potential regulatory interaction with epidermal growth-factor signaling.  
- AKR1B10 (log2FC 6.27): metabolic enzyme shifting retinoid metabolism; indirect relationship via lipid–keratinocyte crosstalk.

**Validation priorities**  
1. **Mechanistic hypothesis**: IL-36 axis centrality. Prioritized because IL36A/IL36G show the largest log2FC and multiple members of the family are upregulated. Dataset evidence: extreme statistical significance. External support: strong psoriasis GWAS and IL-36 mouse models. Next step: CRISPR or neutralizing antibody in human reconstructed epidermis. Conclusion: supported hypothesis.  
2. **Biomarker**: S100A7/A8 serum or tissue levels. Dataset evidence: highest-ranking S100 genes with very high FDR significance. External support: published correlation with PASI. Next step: ELISA validation in longitudinal psoriasis cohorts. Conclusion: supported hypothesis.  
3. **Therapeutic target**: SPRR2 / cornified-envelope genes. Dataset evidence: coherent block of >10 SPRR genes. External support: topical retinoids that normalize SPRR expression improve psoriasis. Next step: topical SPRR2 inhibitor in human skin explants. Conclusion: exploratory hypothesis.  
4. **Interaction / network hypothesis**: CXCL13–CXCR2 axis as recruitment hub. Dataset evidence: both genes strongly upregulated. External support: T-cell trafficking studies in psoriatic plaques. Next step: single-cell RNA-seq with CXCL13 blockade. Conclusion: exploratory hypothesis.  
5. **Confounding / composition check**: epidermal vs. leukocyte origin of S100/DEFB signals. Dataset evidence: all genes highly upregulated. External support: published single-cell atlases showing keratinocyte and neutrophil contributions. Next step: FACS-sorted keratinocyte RNA-seq comparison. Conclusion: exploratory hypothesis.

**Evidence grounding**  
All major programs rest on direct dataset evidence (log2FC magnitude and FDR < 10^{-60} for core genes). Pathway/GO and Reactome annotations provide orthogonal support. Disease-association evidence is strong for IL36, S100, and SERPIN loci via GWAS and prior transcriptomic studies; however, many gene–gene relationships are inferred from co-expression or pathway membership rather than direct physical interaction. No protein–protein interaction databases (STRING, BioGRID) were used to claim direct binding unless independent literature evidence existed. Where evidence overlapped (e.g., multiple SPRR genes), sources were considered independent because they derive from distinct genomic loci and functional annotations.

**Limitations and alternative explanations**  
1. Cell-composition shift: massive dermal neutrophil and T-cell infiltration inflates apparent keratinocyte gene expression; single-cell resolution required to partition signals.  
2. Epidermal hyperplasia is both cause and consequence: the observed differentiation program likely results from IL-17/IL-23 signaling that is not fully captured in this static comparison.  
3. Treatment exposure: patients may have used topical steroids or vitamin D analogs that blunt or exaggerate certain signals; medication history unknown.  
4. Platform/batch effects: although FDRs are uniformly extreme, inter-study normalization differences could affect absolute log2FC.  
5. Downregulated genes (BTC, CYP2W1) are sparse and modest; their functional role may be secondary rather than causative. These factors can be addressed experimentally by FACS-sorted keratinocyte RNA-seq, medication-matched controls, and longitudinal single-cell studies.
